TrialJournal of translational medicine2020

ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer.

J A Kyte et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.